MedTrace Logo

104RA204 Assessment of the Safety and Efficacy of BG9924 in Rheumatoid Arthritis (RA) Participants

NCT00664573 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 339

Last updated 2016-01-21

No results posted yet for this study

Summary

To observe the long-term treatment with BG9924 when administered to participants with RA who previously participated in a Biogen Idec Study.

Conditions

Interventions

BIOLOGICAL

Baminercept alfa (BG9924)

dosage administered as per Biogen-Idec protocol

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Biogen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Argentina
  • Brazil
  • Hungary
  • Mexico
  • Poland
  • Romania
  • Russia
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664573 on ClinicalTrials.gov